Poolbeg Pharma PLC
POLB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £114 | £26 | £26 | £18 |
| Gross Profit | -£114 | -£26 | -£26 | -£18 |
| % Margin | – | – | – | – |
| R&D Expenses | £1,383 | £1,677 | £2,204 | £414 |
| G&A Expenses | £5,258 | £3,376 | £3,060 | £2,031 |
| SG&A Expenses | £5,258 | £3,376 | £3,060 | £1,946 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | -£269 | -£14 | -£278 | £0 |
| Operating Expenses | £6,372 | £5,039 | £4,986 | £2,360 |
| Operating Income | -£6,618 | -£5,039 | -£4,986 | -£2,378 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | £674 | £534 | £209 | £42 |
| Pre-Tax Income | -£5,944 | -£4,505 | -£4,777 | -£2,336 |
| Tax Expense | £154 | -£574 | -£91 | £0 |
| Net Income | -£5,790 | -£3,931 | -£4,686 | -£2,336 |
| % Margin | – | – | – | – |
| EPS | -0.012 | -7.9 | -9.37 | -4.67 |
| % Growth | 99.9% | 15.7% | -100.6% | – |
| EPS Diluted | -0.012 | -7.86 | -9.37 | -4.67 |
| Weighted Avg Shares Out | 499,137 | 498 | 500 | 500 |
| Weighted Avg Shares Out Dil | 500,000 | 500 | 500 | 500 |
| Supplemental Information | – | – | – | – |
| Interest Income | £428 | £534 | £209 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £114 | £26 | £26 | £18 |
| EBITDA | -£5,997 | -£4,660 | -£4,751 | -£2,318 |
| % Margin | – | – | – | – |